INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 102 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2017. The put-call ratio across all filers is 0.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $5,850,000 | +7.7% | 360,000 | 0.0% | 2.31% | +54.5% |
| Q4 2016 | $5,432,000 | -47.2% | 360,000 | -46.7% | 1.50% | -36.9% |
| Q3 2016 | $10,286,000 | -60.7% | 675,000 | 0.0% | 2.37% | -68.1% |
| Q2 2016 | $26,203,000 | +39.6% | 675,000 | 0.0% | 7.44% | +79.9% |
| Q1 2016 | $18,764,000 | -48.3% | 675,000 | 0.0% | 4.14% | -41.4% |
| Q4 2015 | $36,308,000 | +41.7% | 675,000 | +5.5% | 7.06% | +11.5% |
| Q3 2015 | $25,626,000 | +122.8% | 640,000 | +77.8% | 6.33% | +139.1% |
| Q2 2015 | $11,502,000 | +33.8% | 360,000 | 0.0% | 2.65% | +46.0% |
| Q1 2015 | $8,597,000 | +35.3% | 360,000 | 0.0% | 1.81% | -19.4% |
| Q4 2014 | $6,354,000 | +28.7% | 360,000 | 0.0% | 2.25% | +18.0% |
| Q3 2014 | $4,936,000 | +36.1% | 360,000 | +67.3% | 1.91% | +54.5% |
| Q2 2014 | $3,628,000 | +57.5% | 215,202 | +69.9% | 1.23% | +55.6% |
| Q1 2014 | $2,303,000 | – | 126,695 | – | 0.79% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |